What is Genascence?
Founded in 2017 and headquartered in California, Genascence is dedicated to revolutionizing the treatment of prevalent musculoskeletal diseases. The company leverages cutting-edge gene therapy to address chronic conditions that impact millions of patients globally. By moving beyond traditional symptomatic management, Genascence aims to deliver disease-modifying interventions that offer long-term therapeutic benefits. Its market position is defined by a rigorous clinical development pipeline and a commitment to addressing high-unmet-need areas within the orthopedic and rheumatological sectors, effectively bridging the gap between laboratory innovation and patient-centric care.
How much funding has Genascence raised?
Genascence has raised a total of $10.5M across 1 funding round:
Series A
$10.5M
Series A (2022): $10.5M with participation from Pacira BioSciences
Key Investors in Genascence
Pacira BioSciences
Pacira BioSciences is a specialized healthcare entity focused on clinical solutions and therapeutic advancements within the medical sector.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Genascence?
With the recent influx of capital, Genascence is poised to accelerate its clinical trial milestones and expand its research and development capabilities. The strategic roadmap likely involves scaling manufacturing processes for its gene therapy candidates and strengthening its intellectual property portfolio. As the company transitions through its current lifecycle stage, the focus will remain on validating the safety and efficacy of its lead assets in human trials. Investors and stakeholders are closely monitoring the firm's progress as it seeks to disrupt the standard of care for musculoskeletal disorders, potentially setting a new benchmark for gene-based therapeutic interventions in the coming years.
See full Genascence company page
